FDI in 2021: M&A trends
The number of cross-border merger and acquisition (M&A) announcements increased significantly in 2021 with a 45.2% jump compared to the…
16 May 2022
These were the biggest pharmaceutical deals in early 2022
There were 256 deals recorded involving top pharmaceutical companies in the three months to April with a number of high profile contract service agreement, licensing agreement, partnership, merger, venture financing,…
10 May 2022
Top and emerging locations for M&A deals in the pharmaceutical industry
New figures released by GlobalData have shed light on the top locations for mergers and acquisitions in the pharmaceuticals industry. The data shows that M&A activity is strongest in the…
22 Jul 2021
Inside Philip Morris’ controversial Vectura acquisition
Tobacco giant Philip Morris now generates around a quarter of its $28bn sales revenue from smoke-free products and aims to boost this share to more than half by 2025 under…
27 Apr 2021
Science park merger creates UK’s largest life sciences ecosystem
US real estate investment company Harrison Street and UK real estate group Trinity Investment Management this week announced their joint acquisition of Nottingham-based science business incubator BioCity. The £120m deal…
20 Apr 2021
AZ’s proposed acquisition of rare disease-focused Alexion gets US clearance
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC) review. Cambridge-based AstraZeneca (AZ) first announced its intention to buy out…
11 Mar 2021
Exscientia raises $100m Series C funding to develop fully autonomous drug design
Within nine months of closing a $60m Series C round, Oxford-headquartered artificial intelligence (AI) drug discovery company Exscientia has raised an additional $100m in a new Series C financing. This…